Navidea's Lymphoseek meets clinical trial goals for new indication

10/11/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals announced that a Phase III trial of Lymphoseek, its technetium Tc-99m tilmanocept imaging agent, met study goals in terms of sensitivity, negative predictive value and overall accuracy of nonsentinel lymph node diagnosis in assessment of cancer in the head or mouth. The company may submit a supplemental new drug application by the end of the year based on the positive study results.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA